about
Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma.Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy.Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma.Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatoceHepatitis B surface antigen reduction by switching from long-term nucleoside/nucleotide analogue administration to pegylated interferon.Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients.Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients.Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization.Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis.Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications.Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virusReal-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive proceduresTenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarateSorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World PracticeUse of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C PatientsReplyWisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver diseaseThree criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinibValidation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analogNew diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B modeBaseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular CarcinomaNon-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infectionComparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis BRisk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antiviralsValidation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosisHepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir
P50
Q33670826-D41D37E2-7F19-4127-A5A4-4873AC3AA848Q35774186-7FEF1C58-E58C-4D2B-ABFB-3F6F0F4105E9Q36003201-D3B43353-5DC7-4E03-B151-D402CF528629Q37429938-BFD0D4D2-6C7B-417A-8620-0444DB8634FDQ40335324-6A76CD2C-4C1A-4E0C-BCEE-2F8546B3092BQ41624343-72E0F6B3-8222-4E7D-A79B-BBBF0199F1C5Q42249082-C4431E3D-4746-43D8-A480-33EBF2FBF0D2Q48347936-6DBC628E-9671-4FE1-B150-2BD7EC700180Q50277167-14AF79F7-503E-43A2-93A1-A8FD8CE2FA96Q50455508-6AEFA392-0E8D-4E23-91F1-F8C44FE637A5Q50462093-06E0EC6B-3D96-4421-97C0-BAA935C8D472Q59356296-EFEB81DB-A2E2-4773-AAF8-644C58FD26D2Q64246627-AB6E6231-1390-46D8-B7BE-8AE3BFE5688BQ90270266-4F182515-09E5-4110-928F-282016E84723Q90633339-D29B29F7-CC0C-41AB-9BD2-48EC262AA94CQ90813737-09773272-54CC-4BAF-9227-0B20B1B630BCQ91314695-A33A0B3B-D1D4-47D8-96C5-18BEC3DCFB91Q91842340-ACBB7D39-DECD-4CE5-BABA-DB475573D034Q92208608-F191924F-B2A9-4758-9C7A-57719BBA2406Q92895006-6AD61FD4-BFFB-4300-8448-6AFEC2E1FE2BQ92900970-53852715-1E2C-4A6B-8021-DA319B2AAF11Q92960530-B88BE05A-4A43-4810-8926-1F14DB4DA435Q93006375-5EE81194-08FA-4532-88C6-8D9BD3678991Q93026225-2352B368-F279-4099-9306-AFE3F6FE80E0Q93027395-A5868A43-1C03-4577-8C73-090487F654FBQ96221615-A7964A93-8230-48FE-8891-B15805074EE0Q96231769-30D617D2-75D3-4B7D-97E6-87F986333FE6
P50
description
researcher
@en
wetenschapper
@nl
name
N Tamaki
@en
N Tamaki
@nl
type
label
N Tamaki
@en
N Tamaki
@nl
prefLabel
N Tamaki
@en
N Tamaki
@nl
P31
P496
0000-0003-4634-6616